{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-22-000037","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2022-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.841568+00:00","generated_at":"2026-06-23T16:10:14.428966+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexicon amends loan with Oxford Finance; $25M tranche drawable Dec 1-31, 2022","bullets":["First Amendment to Loan and Security Agreement with Oxford Finance LLC executed Aug 29, 2022.","Second $25M tranche draw period changed to Dec 1-31, 2022, subject to conditions and no Event of Default.","Sotagliflozin NDA Milestone already achieved, as confirmed by Collateral Agent.","Amendment fee and Lender Expenses payable; other loan terms unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-22-000037","json":"https://secwatch.observer/filing/0001062822-22-000037.json","markdown":"https://secwatch.observer/filing/0001062822-22-000037.md","text":"https://secwatch.observer/filing/0001062822-22-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282222000037/0001062822-22-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282222000037/lxrx-20220829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T16:10:14.428966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}